Literature DB >> 29320658

Osimertinib as First-Line Treatment in EGFR-Mutated Non-Small-Cell Lung Cancer.

Sanjay Popat1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29320658     DOI： 10.1056/NEJMe1714580

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  14 in total

1.  Predictors of Lung Adenocarcinoma With Leptomeningeal Metastases: A 2022 Targeted-Therapy-Assisted molGPA Model.

Authors:  Milan Zhang; Jiayi Tong; Weifeng Ma; Chongliang Luo; Huiqin Liu; Yushu Jiang; Lingzhi Qin; Xiaojuan Wang; Lipin Yuan; Jiewen Zhang; Fuhua Peng; Yong Chen; Wei Li; Ying Jiang
Journal:  Front Oncol       Date:  2022-06-10       Impact factor: 5.738

2.  Hsp90 inhibitors enhance the antitumoral effect of osimertinib in parental and osimertinib-resistant non-small cell lung cancer cell lines.

Authors:  Jordi Codony-Servat; Santiago Viteri; Carles Codony-Servat; Masaoki Ito; Jillian Willhelmina Paulina Bracht; Jordi Berenguer; Imane Chaib; Miguel Angel Molina-Vila; Niki Karachaliou; Rafael Rosell
Journal:  Transl Lung Cancer Res       Date:  2019-08

Review 3.  Exceptional Response of a Large and Symptomatic EGFR-Mutant Brain Metastasis to Osimertinib: Case Report and Review of the Literature.

Authors:  M Zeeshan Ozair; Alexandra M Giantini Larsen; Juliana Eng; Nelson S Moss
Journal:  JCO Precis Oncol       Date:  2021-04-01

4.  Diagnostic accuracy of droplet digital PCR for detection of EGFR T790M mutation in circulating tumor DNA.

Authors:  Rui Zhang; Bojiang Chen; Xiang Tong; Ye Wang; Chengdi Wang; Jing Jin; Panwen Tian; Weimin Li
Journal:  Cancer Manag Res       Date:  2018-05-16       Impact factor: 3.989

5.  High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases.

Authors:  Marta Laganà; Cristina Gurizzan; Elisa Roca; Diego Cortinovis; Diego Signorelli; Filippo Pagani; Anna Bettini; Lucia Bonomi; Silvia Rinaldi; Rossana Berardi; Marco Filetti; Raffaele Giusti; Sara Pilotto; Michele Milella; Salvatore Intagliata; Alice Baggi; Alessio Cortellini; Hector Soto Parra; Matteo Brighenti; Fausto Petrelli; Chiara Bennati; Paolo Bidoli; Marina Chiara Garassino; Alfredo Berruti
Journal:  Front Oncol       Date:  2020-11-12       Impact factor: 6.244

6.  Mutation and drug-specific intracellular accumulation of EGFR predict clinical responses to tyrosine kinase inhibitors.

Authors:  Maurice de Wit; Ya Gao; Darlene Mercieca; Iris de Heer; Bart Valkenburg; Martin E van Royen; Joachim Aerts; Peter Sillevis Smitt; Pim French
Journal:  EBioMedicine       Date:  2020-06-05       Impact factor: 8.143

7.  EGFR mutations in early-stage and advanced-stage lung adenocarcinoma: Analysis based on large-scale data from China.

Authors:  Can Pi; Chong-Rui Xu; Ming-Feng Zhang; Xiao-Xiao Peng; Xue-Wu Wei; Xing Gao; Hong-Hong Yan; Qing Zhou
Journal:  Thorac Cancer       Date:  2018-05-02       Impact factor: 3.500

8.  A case report of remarkable response to association of radiofrequency ablation with subsequent Atezolizumab in stage IV nonsmall cell lung cancer.

Authors:  Jie Yin; Jingyin Dong; Wei Gao; Yina Wang
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.817

9.  MiRNA therapeutics based on logic circuits of biological pathways.

Authors:  Valeria Boscaino; Antonino Fiannaca; Laura La Paglia; Massimo La Rosa; Riccardo Rizzo; Alfonso Urso
Journal:  BMC Bioinformatics       Date:  2019-11-22       Impact factor: 3.169

10.  Pemetrexed/carboplatin plus gefitinib as a first-line treatment for EGFR-mutant advanced nonsmall cell lung cancer: a Bayesian network meta-analysis.

Authors:  Zhonghan Zhang; Kangmei Zeng; Shen Zhao; Yuanyuan Zhao; Xue Hou; Fan Luo; Feiteng Lu; Yaxiong Zhang; Ting Zhou; Yuxiang Ma; Yunpeng Yang; Wenfeng Fang; Yan Huang; Li Zhang; Hongyun Zhao
Journal:  Ther Adv Med Oncol       Date:  2019-12-30       Impact factor: 8.168
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.